XTNT vs XBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 16, 2026

XTNT

38.8
AI Score
VS
XBIO Wins

XBIO

41.1
AI Score

Investment Advisor Scores

XTNT

39score
Recommendation
SELL

XBIO

41score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric XTNT XBIO Winner
Revenue 43.91M 1.47M XTNT
Net Income -12.50M -1.39M XBIO
Net Margin -28.5% -94.5% XTNT
Operating Income -12.09M -1.47M XBIO
ROE -31.2% -22.8% XBIO
ROA -15.7% -19.9% XTNT
Total Assets 79.67M 6.97M XTNT
Current Ratio 2.16 7.43 XBIO

Relative Price Performance (Last 90 Days)

XTNT 1M: +7.8% · 3M: -16.5% XBIO 1M: -41.3% · 3M: -18.2%

Current Technical Phase

XTNT

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 49

RSI (14): 49.5 · Price: $0.36

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 35

RSI (14): 35.3 · Price: $2.33

Fundamentals Snapshot

Metric XTNT XBIO
Market Cap — —
Forward P/E -11.9 -6.9
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.4% 0.1%
Gross Margin 0.6% 1.0%
Operating Margin -0.2% -1.5%
EPS -0.08 -1.15
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, XBIO is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.